Abhayananda Behera

About

I am a postdoctoral fellow at TMC-ACTREC with a deep passion for cancer biology (Breast cancer and leukemia), focusing on the molecular mechanisms that drive tumor progression, drug resistance, and therapeutic advancements. With a strong foundation in molecular and cellular biology, I have been actively engaged in studying key transcriptional regulators, signaling pathways, and post-translational modifications that influence cancer development.

My research primarily centers on the post-translational modification of critical transcription factors involved in leukemia, aiming to uncover novel regulatory mechanisms that could serve as potential therapeutic targets. Driven by a strong interest in translational research, I strive to bridge the gap between fundamental cancer biology and clinical applications, contributing to the development of innovative treatment strategies.

Through my work, I aspire to make a meaningful impact in the fight against cancer, improving patient outcomes and enhancing our understanding of the intricate mechanisms underlying leukemia and other malignancies.

Employment

• ACTREC Postdoctoral Fellow
  2025 - Present
• University of Hyderabad PhD
  2019 - 2025

Education

• Ravenshaw University MSc
  2016 - 2018
• Fakir Mohan University BSc
  2013 - 2015

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling
  Cell Death 2026 DOI: 10.1016/j.celld.2026.100023
  +Save
• AMPK/mTORC2/AKT-473/RUNX2 signaling axis modulates epithelial-mesenchymal transition and bone tropism in breast cancer
  Frontiers in Oncology 2026 DOI: 10.3389/fonc.2026.1785903
  +Save
• SCF-FBXO31 E3 ubiquitin ligase in cancer: Molecular insights and clinical implications
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2026 DOI: 10.1016/j.bbcan.2026.189534
  +Save
• Role of MARCH E3 ubiquitin ligases in cancer development
  Cancer and Metastasis Reviews 2024 DOI: 10.1007/s10555-024-10201-x
  +Save
• Prostate Cancer
  Biomedical Aspects of Solid Cancers 2024 DOI: 10.1007/978-981-97-1802-3_14
  +Save
• Tumor microenvironment components in pancreatic cancer
  Immune Landscape of Pancreatic Cancer Development and Drug Resistance 2024 DOI: 10.1016/b978-0-443-23523-8.00005-5
  +Save
• WWP1 E3 ligase at the crossroads of health and disease
  Cell Death & Disease 2023 DOI: 10.1038/s41419-023-06380-0
  +Save
• AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects
  Cell Death Discovery 2023 DOI: 10.1038/s41420-023-01700-x
  +Save
• Risk factors and clinical aspects associated with hepatocellular carcinoma: Role of long noncoding RNAs
  Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 1: Biology and Pathophysiology 2022 DOI: 10.1016/B978-0-323-98806-3.00020-9
  +Save
• Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application
  Biochimica et Biophysica Acta - Reviews on Cancer 2021 DOI: 10.1016/j.bbcan.2021.188612
  +Save